Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.53 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 7/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435034 | 0.78 | HCAR3 (0.56) | HCAR3KEAP1SLC9A1HPGDMAPT | |
| SCHEMBL3182817 | 0.76 | HCAR3 (0.59) | HCAR3KEAP1SLC9A1HPGDMAPT | |
| SCHEMBL18911786 | 0.76 | HCAR3 (0.54) | HCAR3KEAP1SLC9A1HPGDMAPT | |
| SCHEMBL1133392 | 0.76 | RAB9A (0.56) | HCAR3KEAP1SLC9A1HPGDMAPT | |
| SCHEMBL4793216 | 0.76 | HCAR3 (0.54) | HCAR3KEAP1SLC9A1HPGDMAPT | |
| SCHEMBL12100525 | 0.76 | HCAR3 (0.54) | HCAR3KEAP1SLC9A1HPGDMAPT | |
| SCHEMBL10287998 | 0.73 | HCAR3 (0.51) | HCAR3KEAP1SLC9A1HPGDMAPT | |
| SCHEMBL31257342 | 0.73 | SMN1; SMN2 (0.57) | HCAR3KEAP1SLC9A1HPGDMAPT | |
| SCHEMBL904701 | 0.72 | HCAR3 (0.50) | HCAR3KEAP1SLC9A1HPGDMAPT | |
| SCHEMBL1525887 | 0.72 | HCAR3 (0.54) | HCAR3KEAP1SLC9A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2119717-B1 | 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as DPP IV inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2018-01-17 | — | — | EP | claimed |
| EP-2350090-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2015-06-03 | — | — | EP | claimed |
| US-8697868-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-15 | — | — | US | claimed |
| US-8263606-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-09-11 | — | — | US | claimed |
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-15 | — | — | US | claimed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | claimed |
| US-20090137801-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | claimed |
| EP-1758905-B1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DDP-IV INHIBITOR | BOEHRINGER INGELHEIM INT (DE) | 2009-04-29 | — | — | EP | claimed |
| US-20050234108-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | claimed |
| US-11173162-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3617205-B1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORP (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20200306256-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2020-10-01 | — | — | US | disclosed |
| US-10632126-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2020-04-28 | — | — | US | disclosed |
| EP-3259269-B9 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORP (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20070142383-A1 | Imidazopyridazinediones, Their Preparation And Their Use As Pharmaceutical Compositions | ECKHARDT MATTHIAS | 2007-06-21 | — | — | US | disclosed |
| EP-1763530-A1 | IMIDAZOPYRIDAZINE DIONES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT | Boehringer Ingelheim International GmbH (DE) | 2007-03-21 | — | — | EP | disclosed |
| US-20060079541-A1 | 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-13 | — | — | US | disclosed |
| US-20060058323-A1 | New 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-16 | — | — | US | disclosed |
| WO-2005087774-A1 | IMIDAZOPYRIDAZINE DIONES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-22 | — | — | WO | disclosed |
| US-20050203095-A1 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142383-A1 | Imidazopyridazinediones, Their Preparation And Their Use As Pharmaceutical Compositions | DPP4, DPP3, DPP7 | HCAR3 2686/4885KEAP1 1496/4885SLC9A1 2184/4885 |
| US-20200306256-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | FGFR4, FGFR3, FGFR1 | HCAR3 527/4885KEAP1 2581/4885SLC9A1 3613/4885 |
| US-10632126-B2 | Bicyclic heterocycles as FGFR4 inhibitors | FGFR4, FGFR3, FGFR1 | HCAR3 1187/4885KEAP1 2736/4885SLC9A1 3083/4885 |
| US-20050203095-A1 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | HCAR3 2607/4885KEAP1 1540/4885SLC9A1 2295/4885 |
| US-20060058323-A1 | New 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP8, DPP4, DPP7 | HCAR3 2074/4885KEAP1 2465/4885SLC9A1 1510/4885 |
| US-20090137801-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP7 | HCAR3 2038/4885KEAP1 2268/4885SLC9A1 977/4885 |
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | CTSA, BECN1, HDAC6 | HCAR3 1559/4885KEAP1 1709/4885SLC9A1 3543/4885 |
| US-11173162-B2 | Bicyclic heterocycles as FGFR4 inhibitors | FGFR4, FGFR3, FGFR1 | HCAR3 1187/4885KEAP1 2736/4885SLC9A1 3083/4885 |
| US-20050234108-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | DPP8, DPP4, DPP7 | HCAR3 2260/4885KEAP1 2305/4885SLC9A1 664/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | HCAR3 611/4885KEAP1 836/4885SLC9A1 295/4885 |
| US-20060079541-A1 | 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP7, DPP3 | HCAR3 1275/4885KEAP1 2257/4885SLC9A1 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.